Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Breo

- PMLiVE

Teva suffers setback as Nuvigil fails late-stage trial

Disappointing results in treating bipolar disorder but drug development continues

- PMLiVE

India’s patents versus India’s patients

What the Roche Pegasys case means for big pharma

- PMLiVE

India could hit Roche and BMS with compulsory licences

Generic versions of Herceptin, Sprycel and Ixempra may reach market before patent expiration

- PMLiVE

Lilly delivers upbeat earnings forecast for 2013

New products will offset generic competition for Alimta, Zyprexa, Cymbalta and Evista

- PMLiVE

Actavis mounts patent challenge on Velcade in US

Plans to launch own version of Takeda’s cancer drug

- PMLiVE

Teva expands presence in South Korea with Handok deal

Will supply products for distribution in market worth $14bn

- PMLiVE

AstraZeneca antitrust fine upheld by European Court of Justice

Lessons for pharma as landmark ruling stands

Dr Reddy’s appoints Umang Vohra to lead US business

Will be replaced as chief financial officer by Saumen Chakraborty

- PMLiVE

Lilly taps Strides Arcolab for cancer generics

Aims to expand its presence in emerging pharmaceutical markets

- PMLiVE

Teva plans revamp as 2013 revenues expected to fall short

Expects increased competition for biggest-selling drug Copaxone

Cipla appoints Novartis’ Subhanu Saxena as CEO

Was previously head of global product strategy and commercialisation at Swiss pharma firm

- PMLiVE

Lundbeck revenues fall on Lexapro competition

Reinforces need for successful vortioxetine launch

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links